- Home
- CNTY vs INMB Comparison
CNTY vs INMB Comparison
Compare CNTY & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTY | INMB |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0M | 57.9M |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CNTY | INMB |
|---|---|---|
| Price | $1.27 | $2.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $3.00 | ★ $5.40 |
| AVG Volume (30 Days) | 66.3K | ★ 334.7K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.31 | 11.85 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $430,529,000.00 | $50,000.00 |
| Revenue This Year | $7.17 | N/A |
| Revenue Next Year | $3.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 10.82 | ★ 257.14 |
| 52 Week Low | $1.14 | $1.09 |
| 52 Week High | $2.81 | $2.34 |
Technical Indicators
Market Signals| Indicator | CNTY | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 52.77 | 69.94 |
| Support Level | $1.24 | $1.37 |
| Resistance Level | $1.34 | N/A |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 56.25 | 81.88 |
Price Performance
Historical ComparisonAbout CNTY Century Casinos Inc.
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has five reportable segments based on the geographical locations in which its casinos operate; US East, US Midwest, US West, Canada, and Poland.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.